December
29, 2005
Drug-Eluting
Stents May Cause Allergic Reactions
A new study appearing in next week's Journal of the American College of Cardiology
reports on a phenomenon that is not news to us here at Angioplasty.Org: allergic
reactions to drug-eluting stents. Our Forum
Topic has received almost 90 postings from patients on the subject, most
in the past two years since the introduction of drug-eluting stents. The Northwestern
study used a number of sources for the adverse reactions, among them the FDA
MAUDE database. The study found definite allergic reactions to the stents themselves
-- possibly to the polymer coatings on the stents. Symptoms included rash, difficulty
breathing, hives, itching and fevers. (Read
more...)
December
13, 2005
Guidant
Enrolls First Patient in Japan Arm of Drug Eluting Stent
Trial
(source: Guidant Corporation)
The company announced today that it has now begun enrollment in the Japan arm
of its SPIRIT III drug eluting stent clinical trial evaluating XIENCE™ V, an
everolimus eluting coronary stent system utilizing Guidant's cobalt chromium
MULTI-LINK VISION® Coronary Stent System rapid exchange platform.
December
13, 2005
Medtronic
Announces First Clinical Trial Experience With Next-Generation
Drug-Eluting Coronary Stent System
(source: Medtronic, Inc.)
This next-generation drug-eluting stent will use the popular Driver™ bare metal
cobalt alloy stent platform and the drug Zotarolimus (ABT-578), licensed from
Abbott, along with the proprietary, biocompatible drug delivery polymer developed
by Medtronic. Prof. Ian Meredith, Monash Medical Centre, is the principal investigator
of the Medtronic RESOLUTE clinical study evaluating the new stent. This first-in-man
study will enroll up to 100 patients at 12 clinical sites in Australia and
New Zealand. The new polymer will allow more precise and adjustable rates of
drug release.
related stories:
Medtronic
begins test of new stent -- Reuters
December
1, 2005
Italian
Ministry of Health Assigns Higher Price Premium to CYPHER® Sirolimus-Eluting
Coronary Stent
(source: Cordis Corporation)
According to this company press release from Cordis / J&J, the Italian
government's Commissione Unica Dispositivi medica (CUD) – the National Committee
for Medical Devices -- has decided to pay more for the Cypher drug-eluting
stent -- a 23% higher price than other drug-eluting stents on the market, due
to lower costs associated with re-intervention. Brian G. Firth, Cordis worldwide
VP of medical affairs and health economics, states, "CUD's analysis has shown
that initial treatment costs combined with minimal costs of follow-up and long-term
care for patients with the CYPHER® Stent offer a clear advantage over other
commercially available drug-eluting stents."
December
1, 2005
Conor
Medsystems Receives FDA Approval for Full Expansion of
COSTAR II Drug Eluting Stent Trial
(source: Conor Medsystems, Inc.)
The company announced that it has received FDA approval to expand its randomized
clinical trial to a full cohort of 1,700 patients. The trial will compare Conor's
COSTAR II drug-eluting stent to Boston Scientific's Taxus (patent lawsuit and
countersuits have been filed). The results should be more than interesting
because Conor's stent uses the same drug (paclitaxel) as the Taxus, but the
drug delivery system differs. In the Boston stent, a polymer which controls
the release dose of the drug is coated on the entire stent. The drug gets released
in the first few months and the inner lining of the artery covers the polymer-coated
stent over time. In the Conor stent, a bioresorbable polymer containing the
drug is loaded into hundreds of small holes or reservoirs in the stent's metal
surface. Once the polymer has released its drug over time, it is absorbed into
the body, leaving no residue, and the Conor COSTAR II stent, for all intents,
becomes a bare metal stent. There have been some concerns (most recently expressed
by Dr. Renu Virmani at this year's TCT) that non-resorbable polymers on the
two currently available drug-eluting stents may delay healing of the artery
and be a cause for late stent thrombosis (clotting) which, while low in occurrence,
is fatal almost half the time. Her research showed no such effect in bare metal
stents, so the results of the CONOR trial will be closely watched.
related stories:
Conor
says FDA approves widened stent trial -- Reuters
Suit
and Countersuit: Angiotech Trades Barbs with Conor Medsystems -- Medical
DeviceLink
November
29, 2005
SurModics'
Hydrophilic Coating on Medtronic Endeavor™ Drug-Eluting
Stent Delivery System
(source: SurModics, Inc.)
Company announces that it has licensed its advanced hydrophilic technology
to Medtronic for use on their Endeavor drug-eluting stent delivery system to
make the catheter that carries the stent more "lubricious". SurModics
also makes the BRAVO™ polymer that is used on Cordis/J&J's Cypher™ stent.
November
28, 2005
Drug-coated
stents equally effective
(source: Karen Garloch, Charlotte Observer)
A report quoting Dr. Charles Simonton of the Sanger Clinic in Charlotte, North
Carolina, who headed up the 14,000 patient STENT
Registry, comparing the Taxus and Cypher stents. He states, "These two
stents are performing almost identically.... There's no reason why an interventional
cardiologist ought to pick one over the other based on the way patients are
turning out."
related stories:
Trends
Favour Boston Scientific's TAXUS Stent Over J&J's Cypher in Interim
9-Month Data From Largest Independent DES Registry in US -- Boston
Scientific
The Company has a slightly different interpretation of the data
than the STENT registry's lead investigator.
Déjà Lu: "already
read" -- Voice in the Ear: The Stent
Blog
Can you step into the same press release twice?
November
26, 2005
Boston
Scientific Says Its Stent Has An Edge Over J&J
(source: Wall Street Journal $$)
Paul LaViolette, COO of Boston Scientific, tells the Wall Street Journal that
a study the company commissioned showed that its Taxus stent may have a "considerable
advantage" over the competing Cypher stent, made by Johnson & Johnson.
A review and analysis of FDA "adverse report" records made by Certus
International showed a significantly larger number of reports of restenosis
(renarrowing) or thrombosis (clotting) with the Cypher stent. Terri Mueller
of Cordis/Johnson & Johnson called Boston Scientific's statement "inappropriate
and misleading," while Dennis Donohoe, Cordis' VP for regulatory affairs
pointed out that the FDA database was not meant to be used for these types
of analyses, which are better determined through clinical trials. The ongoing "Stent
Wars" between these two rivals have bred much controversy. Most clinical
trials have shown the two stents roughly equivalent in regard to thrombosis
and restenosis; some smaller single center trials have shown that Cypher is
better at preventing restenosis.
related stories:
My
Night With MAUDE -- The Voice in the Ear:
The Stent Blog
Can the FDA adverse events database really be used to show
superiority of one device over another? Here's a hint: NO!
November
16, 2005
J&J-Guidant
merger to shake up stent market
(source: Stephen Heuser, Boston Globe)
An analysis of the impact of J&J buying Guidant on Boston Scientific and
the stent market in general.
November
15, 2005
Boston
Scientific questions Michigan center's complaints
(source: St. Paul Pioneer Press/Bloomberg News)
Boston Scientific said problems with its heart
stents at Michigan's busiest cardiac center haven't occurred elsewhere and,
according to this article, suggested that doctors may have mishandled the devices. "It
is essential to follow the directions for use...It appears that some individuals
at Beaumont are not satisfied, but their dissatisfaction is out of all proportion
to our experience at more than 1,000 cardiac catheterization labs,"" said
Boston Scientific spokesman Paul Donovan.
November
15, 2005
Guidant
Reports Excellent 12-Month Results from SPIRIT FIRST Everolimus
Eluting Coronary Stent Clinical Trial
(source: Guidant Corporation)
One year results from the XIENCE V drug-eluting stent were impressive, says
principal investigator Prof. Patrick W. Serruys, M.D. of Rotterdam. He continues, "The
benefit of an everolimus drug eluting stent, with only one device-related MACE
event and no thrombotic events, combined with the highly deliverable rapid-exchange
VISION stent and stent delivery system, holds great promise for the treatment
of patients with cardiovascular disease." Results were presented at the AHA
Scientific Sessions in Dallas.
November
14, 2005
Hospital's
Suspension of Boston Scientific Stent Gets FDA Review
(source: Wall Street Journal $$)
According to an article in today's Wall Street Journal, the FDA is evaluating
the temporary suspension in the use of the Taxus stent enacted 7 weeks ago
by Dr. William O'Neill of William Beaumont Hospital in Michigan, where over
a 5-day period, three Taxus system balloons had difficulty being withdrawn,
and caused some injury to arterial linings. The problem is different than the
one which prompted a voluntary recall of the Taxus stent in the summer of 2004,
which had to do with a possible weak laser weld in the catheter shaft. This
new problem, if in fact it is one, seems related to the balloon, not the stent.
A stent is delivered to the artery on a balloon which is inflated, thus expanding
the stent into the desired position; the balloon is then deflated and pulled
out, leaving the stent behind. Withdrawal of the balloon should be uneventful,
which doesn't seem to be the case here. There have been some perceptions of
balloon "stickiness" since soon after the Taxus stent was introduced
although, according to a company spokesperson, complaints are less than 1 in
10,000. Some physicians have posited that the polymer coating of the stent
can cause the balloon to stick to the expanded stent and have difficulty deflating
or withdrawing after the stent has been delivered. Use of the stents was reinstated
by Dr. O'Neill after assurances from the company were made that there were
no defects in the product and Boston Scientific trainers visited the hospital
to work with the doctors. At issue is a complaint from Dr. James Goldstein,
a cardiologist at the hospital, that Boston Scientific implied the issue has
been "solved". His feeling is that the problem has not been solved
-- and now the FDA has stated that it "does not consider this situation
to be a 'closed' matter." Stay tuned.
related stories:
FDA
reviews Taxus complaints in Michigan -- Reuters
November
10, 2005
Guidant
Completes Enrollment in International Drug Eluting Stent
Clinical Trial
(source: Guidant Corporation)
SPIRIT II is a 300-patient randomized clinical trial evaluating XIENCE™ V,
an everolimus eluting coronary stent system utilizing Guidant's cobalt chromium
rapid-exchange MULTI-LINK VISION® Coronary Stent System platform. Prof. Patrick
W. Serruys, M.D., of the Thoraxcenter, Erasmus University Hospital, Rotterdam,
serves as the trial's principal investigator. "The SPIRIT II trial will continue
to evaluate the clinical experience of XIENCE V, which demonstrated excellent
six-month results in the SPIRIT FIRST trial reported last fall," said Prof.
Serruys. "We look forward to the presentation of additional results from SPIRIT
FIRST at the American Heart Association Scientific Sessions next week."
October
27, 2005
Competing
medicated stents work equally well - Most comprehensive
USA clinical trial to date shows
(source: Carolinas HealthCare System)
After completing the most comprehensive U.S.-based study of its kind, Dr. Charles
Simonton reported that the performance of two competing coronary stents was “virtually
identical” in head-to-head comparisons. The STENT registry, which now
includes approximately 14, 000 patients, is the first of its kind to gather
data from multiple sites, including eight medical centers located throughout
the Southeast. The registry also includes one of the largest patient follow-up
efforts based on a profile of the general populace.
related stories:
TAXUS® Stent
Demonstrates Excellent Efficacy and Safety in Independent 'STENT' Registry -- Boston
Scientific
Press release from the manufacturer of the Taxus stent claims
a "numeric trend" favors their stent.
The
Numbers Game-- The Voice in the Ear
Commentary on statistical claims and the marketing of
stents and how it affects patients.
October
22, 2005
Boston
Scientific Heads to the Recovery Room
(source: Barron's Online)
An interesting overview of the rises and falls of Boston Scientific in the
drug-eluting stent era. When Boston's Taxus was introduced in
March 2004, it quickly captured two-thirds of the market. Then last summer's recalls,
along with studies presented
at the ACC in March which seemed to show Cypher superiority (even though
the major trial was in fact a draw) -- these events took their toll and last
Tuesday, J&J proudly reported that Cypher U.S. market share had increased
to 46%. Boston hopes to regain much of this lost business with its new Liberte
stent, hopefully to be approved later this year or early 2006. But the company
still seems to be on the defensive -- Chief Financial Officer Larry Best complains
in the article, "We've got a growth story with Taxus, and no one wants
to listen to it." And later he says management would even entertain offers
for the entire company. "We're shareholders," he says, "and
everything's for sale." Insiders, a group to which Mr. Best would belong,
own 35% of the company.
October
21, 2005
Some
Doctors See Long-Term Clot Risk In Stent Patients
(source: Wall Street Journal -- $$)
We at Angioplasty.Org have been on this story for two
years now. Back in the fall of 2003, some late stent thrombosis that appeared
in Cypher patients caused alarm. The data were investigated and it was concluded,
correctly so, that the stent thrombosis rate of less than 1% was comparable
to that seen in bare metal stents. When Taxus stents were introduced, most
studies showed similar rates (notwithstanding Johnson & Johnson / Cordis'
campaign that attempted to imply that Taxus was less safe). Then just this
spring came a study
from Antonio Colombo's group that showed a real-world thrombosis rate double that
in the clinical studies. And now several reports at the TCT are showing a small
number of patients who have developed thrombosis (clotting) at up to three
years. Dr. Renu Virmani showed her study of 40 drug-eluting stent patients
who had died from cardiac causes -- 60% of them had a blood clot in their drug-eluting
stent. Of great importance was the fact that all these patients also had bare
metal stents from earlier interventions: none of these stents showed clots.
So the late stent thrombosis problem seems to be a class effect for drug-eluting
stents, emphasizing that antiplatelet therapy is critical after the procedure
and more and more doctors now think should be extended well beyond the recommended
minimum 3-6 months.
related stories:
"Free" reprint
of above WSJ article -- Pittsburg Post-Gazette
Doctors
study risk of clots in new stents -- Boston
Globe
October
21, 2005
Conor
Medsystems Presents Positive Clinical Data From EuroSTAR
and COSTAR I Studies
(source: Conor Medsystems, Inc.)
The data from two studies have solidified Conor's decision to move forward
with a dose of 10mcg of the drug paclitaxel on its drug-eluting stent the CoStar,
which may see approval in Europe by the end of this year. The results show
restenosis rates similar to those of the two currently U.S.-approved stents
made by Boston Scientific and Cordis. The CoStar embodies a different design
which the company touts as being crfeated specifically for drug delivery, rather
than being an older bare metal stent that has been retrofitted for that purpose.
Several potential advantages of the CoStar are ease-of-use, more deliverability,
and the complete absorption of the drug and its delivery medium by the body,
leaving no polymer behind after about 6 months -- this may have implications
in the growing concern over late stent thrombosis (blood clots that may develop
even 1 or 2 years after implantation of polymer-coated drug-eluting stents
-- this only has occurred in a small percetnage of patients, but it is very
serious) -- the CoStar has shown no stent thrombosis so far.
related stories:
Crashing
The Stent Party -- BusinessWeek Online
Conor
Medsystems to Pursue Drug Stent -- Associated
Press
October
21, 2005
Sirolimus-Eluting
Coronary Stent Outperforms Paclitaxel Eluting Stent in
Seven Study Meta-Analysis
(source: Cordis Corporation)
In this press release, a seven study "meta-analysis" shows the Cypher
stent outperforming the Taxus stent. While it is true that virtually all studies
have shown the Cypher sirolimus stent to be equal to or slightly better than
its Taxus paclitaxel rival in TLR (Total Lesion Revascularization) one can
also find that the two are equal, depending on which definition of success
one uses. For example, the TCTMD.com's "Evidence-Based
Medicine Center". using guidelines fashioned along those of the European
Society of Cardiology, finds that Taxus and Cypher are not so different --
of course, the EBMC is "is made possible by support from Boston Scientific
Corporation".
October
20, 2005
TAXUS® Express2™ Stent
System Shows Significant Reduction of Restenosis in Diabetic
Patients in Clinical Trial
(source: Boston Scientific Corporation)
A subset of data from Boston Scientific's Taxus V clinical
trial showed marked reduction in restenosis for diabetic patients,
who are at increased risk for having their arteries close up
again after stenting. At 9-months the Taxus stent group had
a reclosure rate of 9.6 percent compared with 17.5 percent
in the control group of bare metal stents -- a 45% reduction,
interestingly the same amount of reduction as in the non-diabetic
population -- the Taxus stent restenosis prevention effect
seems to work across the board.
October
20, 2005
New
Analysis Suggests the CYPHER® Sirolimus-Eluting Coronary
Stent is Cost Effective in the Treatment of Multi-Vessel
Disease Versus Bypass Surgery
(source: Cordis Corporation)
This analysis shows that the use of drug-eluting stents over bypass surgery
is less expensive by 21-29%, even though drug-eluting stents, such as the Cypher,
cost between $2,000-3,000@.
October
20, 2005
OLYMPIA
Registry Supports Positive Safety Profile of TAXUS® Liberte™ Stent
System
(source: Boston Scientific Corporation)
The company moves forward with its Liberte platform.
October
20, 2005
Study
Finds Excellent Results in Patients with Long Lesions Treated
with Multiple and Overlapping CYPHER® Sirolimus-Eluting
Stents
(source: Cordis Corporation)
Dr. Campbell Rogers of Brigham & Women's Hospital in Boston presented a detailed
analysis of data pooled across four drug-eluting stent clinical trials at this
year's TCT. The analysis finds that high risk patients with long coronary blockages
had better clinical outcomes with multiple, overlapping or non overlapping,
CYPHER® Stents than those patients who received bare metal stents.
October
17, 2005
New
Study Results Suggest Better Outcomes With The CYPHER® Sirolimus-Eluting
Coronary Stent Than Brachytherapy In Patients With In-Stent
Reblockage
(source: Cordis Corporation)
Not that this is any surprise, since brachytherapy (radiation therapy) is not
really being used much anymore in interventional procedures. The conundrum
here is that brachytherapy is currently the ONLY FDA-approved treatment
for in-stent restenosis, yet it's been known that drug-eluting stents work
better -- cardiologists in fact sometimes use them "off-label" --
perhaps studies such as this will help the FDA expand the approved indications.
October
17, 2005
ENDEAVOR
III Confirmatory Study Demonstrates Clinical Outcomes Consistent
With Previous Endeavor Trials
(source: Medtronic, Inc.)
The headline doesn't read this way, but the Endeavor III Trial, as some had
predicted, failed to meet its endpoint, albeit very narrowly, to show non-inferiority
with the Cypher stent. The real meaning of this is that Medtronic's entry into
the U.S. market may be delayed since the FDA may want to see the results of
Endeavor IV before granting approval. (Endeavor IV pits the Medtronic stent
against Boston's Taxus.) Medtronic still feels that they will see approval
in 2007; others in the device industry have told Angioplasty.Org they think
2008 may be more realistic.
related stories:
Medtronic
stent study narrowly misses goal -- Reuters
Medtronic
Stent Undershoots Target -- TheStreet.com
October
14, 2005
Cordis
Corporation Announces Broad Range of Clinical Studies and
Events for the CYPHER® Sirolimus-eluting Coronary Stent
at TCT 2005
(source: Cordis Corporation)
Schedule for presentations of drug-eluting stent trials, etc. at next week's
big interventional cardiology meeting in Washington.
October
14, 2005
Boston
Scientific cuts outlook amid loss
(source: Debra Sherman, Reuters)
Due to its $750 million settlement with Medinol and lower domestic sales on
their Taxus drug-eluting stent, Boston Scientific reported a loss in its 3rd
quarter.
related stories:
Boston's
Forecast Comes Up Short -- TheStreet.com
October
13, 2005
Boston
Scientific Wins Appeal in Patent Infringement Case Against
Johnson & Johnson in the Netherlands
(source: Boston Scientific Corporation)
Back in June, a Dutch court ruled
against Cordis on a patent infringement issue involving not
their stent, but the shaft of the catheter used to deliver the stent-on-a-balloon.
The court also issued an injunction against the sale by Cordis of products
using this patent (this included the Cypher). Cordis appealed the verdict and
in July, another court lifted the injunction temporarily while the full apeal
was being decided upon. Today the court ruled against J&J/Cordis and the
injunction is now back in full force.
related stories:
Boston
Scientific wins Dutch patent appeal over J&J -- Reuters
October
13, 2005
Boston
Scientific Announces 'TAXUS® Stent Assurance Program'
(source: Boston Scientific Corporation)
In a first-of-kind program, the company announced that it will replace for
free any Taxus stent that requires re-intervention in a patient. The offer
will run during calendar year 2006 and is good only to hospitals that enroll
in the program through their sales representatives. More details can be found
in this description on
Boston Scientific's website. (comment
on this story.)
related stories:
Stent
maker to offer free replacements -- Boston Globe
Dr. Campbell Rogers, a cardiologist at Brigham and Women's
Hospital, said the guarantee was ''intriguing" but questioned
whether it would be practical for doctors and hospitals to reap the
benefits. The terms of the deal require hospitals to pre-enroll with
a Boston Scientific salesperson and submit multiple documents to
prove the artery has reclogged inside the stent.
Boston
Scientific sees no Taxus share loss in quarter -- Reuters
Paul LaViolette (COO of the company) states that there
has been no loss of market share to Johnson & Johnson's competing
Cypher stent in the 3rd quarter (this is contrary to some analysts'
predictions) and also that all problems stemming from last summer's
recall are fixed "definitively". The article has also
been recently updated to include commentary on Boston's "money-back
guarantee".
October
11, 2005
Medtronic
to present key drug-eluting stent data next week
(source: Daniel Rosenberg, MarketWatch.com)
Good overview of the issues facing Medtronic next Monday when the data from
the Endeavor drug-eluting stent trials is presented at the TCT
meeting in Washington.
October
10, 2005
Never
a Dull Moment for Device Makers
(source: Althea Chang, TheStreet.com)
An good wrap-up of where the various stent companies stand, as they approach "TCT-week",
starting next Sunday..
October
10, 2005
Boston
Scientific to Release Long-Term Clinical Trial Results
on Market- Leading TAXUS® Express2™ Coronary
Stent System at TCT 2005
(source: Boston Scientific Corporation)
Schedule for presentations of drug-eluting stent, carotid trials, etc. at next
week's big interventional cardiology meeting in Washington.
October 10, 2005
Medtronic,
Inc. Webcast Notice: Medtronic Vascular Update
(source: Medtronic, Inc.)
Schedule for webcast at next week's TCT interventional cardiology meeting in
Washington.
October
10, 2005
Johnson & Johnson
Outlook Boosted By Cypher
(source: Forbes.com)
Several analysts expect Johnson & Johnson to announce strong gains in market-share
of drug-eluting stent, following Boston Scientific's problems over the summer
and clinical studies that have shown Cypher edging out the Taxus in the most
complex patients.
October
10, 2005
Medtronic
Submits First PMA Module to the U.S. Food and Drug Administration
for Endeavor™ Drug-Eluting Coronary Stent
(source: Medtronic, Inc.)
Kind of "they're off!" in the stent races -- Medtronic is starting
the process in the U.S. that it hopes will lead it to become the third drug-eluting
stent marketed there.
October
6, 2005
FTC
ruling key to Medtronic stent plans
(source: Reuters)
While results from Medtronic's latest clinical trial for its Endeavor drug-eluting
stent will be presented at this year's TCT, a bigger question for the company's
future program will be an FTC ruling about whether Johnson & Johnson will
be required to license its rapid exchange technology to other companies as
part of its planned merger with Guidant. If it is, J&J is expected to license
the technology to Abbott, in a bid to keep Medtronic from overtaking a share
of its market (currently shared with Boston Scientific). A rapid exchange system
(which J&J, Guidant and Boston all have) is considered critical to success
in the angioplasty market.
October
6, 2005
Guidant
Launches Cobalt Chromium Coronary Stent System in Japan
(source: Guidant Corporation)
The rapid-exchange MULTI-LINK VISION® RX Stent System is made of cobalt
chromium, unlike the current generation of metal stents which are made of stainless
steel. Cobalt chromium is a stronger metal, thus allowing a stent to be made
with thinner struts -- exposing less stent to the bloodstream and hopefully
lowering the restenosis rate. Guidant is using the VISION stent as the foundation
for its own drug-eluting stent program, the XIENCE™ V, currently in a
clinical trial comparing it to Boston Scientific's Taxus.
October
6, 2005
Cook
Launches Web Site for Patients Seeking Information About
Peripheral Arterial Disease
(source: Cook Inc.)
The new website includes information about symptoms, prevention and treatment
of Periperal Arterial Disease (PAD). Consumers also can download information
to determine with their physicians whether they may be eligible to participate
in a worldwide clinical trial testing the safety and effectiveness of the Zilver® PTX™ Drug-Eluting
Stent. This is the first-ever clinical trial to test a paclitaxel-eluting stent
to treat PAD.
October
3, 2005
Drug-Coated
Stents Better for Diabetics
A study of 160 patients from Spain adds to the growing body of evidence that
diabetics, a patient population previously considered high risk for reblocking
after angioplasty/stenting, can be successfully treated with drug-eluting (drug-coated)
stents. Comparing bare metal stents to a drug-eluting sirolimus stent (this
would be the Cypher, made by Cordis/J&J) the need for a repeat angioplasty
was 5 times higher in the bare metal group; the occurrence of a Major Adverse
Cardiac Event (MACE) was almost 4 times higher. A spokesman for the American
Heart Association states in the article that the study is "good news for
patients with diabetes."
(source: Ed Edelson, HealthDay)
September
26, 2005
Medinol
to seek royalties from Boston Scientific
(source: MSNBC)
In the "not so fast" category, less than a week after announcing
a settlement (see below) of
its long-standing dispute with Medinol, Boston Scientific finds itself again
the target of legal action by the Israeli firm, which is now claiming royalties
due from the Taxus Liberte stent, Boston Scientific's second-generation device,
now approved in Europe. While Boston Scientific feels the claims are without
merit, J.P. Morgan analyst Michael Weinstein states, "The issue for investors
is that the Boston Scientific press release made it seem like there was closure
to the Medinol issue, when clearly there is not.... What Medinol said today
is, no, there is not closure after October 25."
September
26, 2005
U.S.
FTC eyes licensing plan for J&J-Guidant deal
(source: Reuters)
In a new wrinkle to the possible requirement that J&J/Guidant share their "rapid
exchange" technology to gain merger approval from the Federal Trade Commission,
recent reports are that they may be directed to license the technology specifically
to Abbott, leaving Medtronic and other balloon and stent manufacturers out
in the cold. Medtronic is not pleased with this turn of events, and is taking
its objections directly to the four FTC commissioners.
September
23, 2005
Battle
of the Drug-Eluting Stents
(source: Journal Watch Cardiology)
Commentary on the several studies published
in August comparing the sirolimus (Cypher) and paclitaxel (Taxus) drug-eluting
stents. Conclusion was that the sirolimus peformed somewhat better in terms
of less restenosis, but that "for many patients, the sirolimus stent’s
clinical advantages might be outweighed by the paclitaxel stent’s greater
ease of delivery and by cost differences." Also with a new generation
of stents coming along, these conclusion may need revision.
September
21, 2005
Boston
Scientific and Medinol Announce Settlement
(source: Boston Scientific Corporation)
The long-standing legal dispute between Israeli-based Medinol and Boston Scientific
has been resolved -- and for the mere price of $750 million dollars!! Briefly
stated, Boston Scientific had an exclusive supply agreement with Medinol for
stents (a model no longer marketed -- the NIR stent) but when difficulties
arose between the two, Boston Scientific secretly reverse-engineered the NIR
and built an assembly line behind locked doors in their Ireland plant. This
information was communicated to Medinol by Jim Tobin, CEO of Boston Scientific,
who admitted it was wrong. However, Boston claimed that Medinol has reneged
on their agreement to supply sufficient stents and that Boston took its action
to protect its product availability. Medinol also claimed that Boston Scientific
infringed on their stent patents in the design of the currently marketed Express
and Taxus Express stents. Kobi and Judith Richter, owners of Medinol, previously
rejected smaller settlement offers. While this agreement represents a large
cash outlay for Boston Scientific, it brings to a close a big unknown that
had the investment community concerned about whether a court might order an
injunction against sale of the Taxus stent, Boston Scientific's big profit-center.
Boston
Scientific settles with Medinol for $750 mln -- Reuters
Boston
Scientific Settles Spat -- Wall Street Journal
($$)
September
19, 2005
J&J/Guidant
may license stent technology
(source: Susan Kelly, Reuters)
J&J and Guidant may have to make their "rapid exchange" technologies
available to other companies for purchase in order to gain Federal regulators'
approval of their upcoming merger. Neither Medtronic nor Abbott, who are looking
at 2006-7 for introduction of their drug-eluting stents into the U.S. market,
currently have this technology and both are anxious to get it. Boston Scientific
has its own rapid exchange system (gained when it acquired Schneider -- the first
manufacturer of angioplasty devices) and probably has the most to lose
from this licensing. In brief, rapid exchange is a two-handed system which
allows one operator (the cardiologist) to perform the entire angioplasty; the
original system requires four hands: two to hold the guiding catheter and advance
the balloon or stent and two more to hold and steer the guide wire component,
requiring the cardiologist and an assistant.
Medtronic
May Seek to Buy Popular Stent Technology -- Wall
Street Journal ($$)
September
16, 2005
Medtronic
Completes Patient Enrollment In Endeavor III Clinical Trial
(source: Medtronic Inc.)
The company has completed enrollment in its clinical trial, comparing the performance
of its Endeavor drug-eluting stent to that of the Cypher sirolimus stent, made
by Johnson & Johnson/Cordis. Results of this trial will be presented at
this October's TCT meeting in Washington.
September
4, 2005
Key
Clinical Data Shows That The Endeavor™ Drug-Eluting
Stent Sustains Strong Safety And Efficacy Performance Over
Time
(source: Medtronic Inc.)
The first two Endeavor trials were reported at 12 and 24 months with the results
that restenosis has been kept in check and there has been no late stent thrombosis.
Results from the Endeavor III trial will be announced at the TCT conference
in October.
September
1, 2005
Importance
of Antiplatelet Therapy with Drug-Eluting Stents
(source: U.S. Food and Drug Administration)
A problem that Angioplasty.Org has been stressing for two
years now: the danger of premature withdrawal of antiplatelet
therapy (aspirin and/or Plavix). In the fall of 2003, not long after Johnson & Johnson's
Cypher stent was approved, reports started coming in about late stent thrombosis
-- the sudden (and often fatal) formation of a blood clot at the site of the
stent. This only occurred in a very small number of patients and, as we suggested
then and several studies have since proven, the cause of some of this thrombosis
is that patients stopped taking their antiplatelet drugs. Sometimes they were
told to because they needed to have surgery, or a dental procedure. Read the
FDA's warning -- it's even on video.
August
24, 2005
Warning
Letter to Boston Scientific -- Dated August 10, 2005
(source: U.S. Food and Drug Administration)
Yesterday the FDA made public a fairly strong warning letter it had sent to
Boston Scientific regarding problems at its Quincy, Massachusetts shipping
facility in which somehow drug-eluting stents that had been quarantined for
failure to pass a quality control test were shipped to 5 hospitals. Supposedly
this occurred when an employee or employees over-rode a computer block on these
items. Charles Rudnick, a spokesperson for the company stated that "None
of the products resulted in any harm to patients." He continued that they
were shipped in error and, in most cases, had been retrieved from the hospitals
immediately.
Boston
Sci receives FDA warning -- MarketWatch.com
August
16, 2005
Studies
Give Edge To J&J Stent
(source: Forbes)
Two studies to be published this week in New England Journal of Medicine and Journal
of the American Medical Association show that J&J's Cypher is superior
to Boston Scientific's TAXUS drug-eluting stent. Previously reported at the
ACC in March, the SIRTAX and ISAR-DIABETES full studies will appear in NEJM,
while a meta-analysis of almost 4,000 patients by Dr Adnan Kastrati of Munich
will be published in JAMA. While the differences between stents are not large,
they do seem to exist. One problem, however, is the supply of Cypher stents
in all sizes is still not up to full levels; also in some cases, the Taxus
seems easier to deliver to the artery.
American
Journal of Cardiology Study Finds TAXUS Has Lower MACE Rate Than Cypher
(source: Boston Scientific Corporation)
Showing the exact opposite of the above trials and analyses, a small Dutch
study of 293 patients showed that Taxus bested Cypher in 2 of 3 areas known
as MACE (Major Adverse Cardiac Events) and basically tied in the third.
New
meta-analysis rekindles Cypher-Taxus debate, fueled by publication
of SIRTAX and ISAR-DIABETES
(source: theheart.org -- registration required)
A detailed report on these two studies with opinions from various
cardiologists, our favorite is from Ron Waksman of the Washington
Hospital Center who stated, "I think a large part of this is
propaganda. Cordis is trying to show that its stent is superior to
Boston Scientific's, and Boston Scientific is trying to show that
there is no difference. So each company will pick up the pieces from
the studies that fit their statements. When we look at our own Washington
Hospital Center data, which now cover 2,500 patients, they do not
show any difference between the two stents."
July 31,
2005
Medtronic
Receives CE Mark Approval For Endeavor™ Drug-Eluting
Coronary Stent System
Mark that number three -- Medtronic's Endeavor drug-eluting stent has now achieved
the significant approval of the European community and the company is looking
toward an U.S. approval next year, making the endeavor the third DES available.
The Medtronics stent, interestingly enough, is coated with a drug made by Abbott,
a company that is developing its own drug-eluting stent.
(source: Medtronic, Inc.)
July 19, 2005
Stent
maker says legal disputes not major threat
Boston Scientific responds to concerns that its legal disputes with Johnson & Johnson
and Medinol will become significant negatives for the company.
(source: Ross Kerber, Boston Globe)
July 14,
2005
Stent
report dismissed
Both Boston Scientific and Federal regulators state that the problems raised
in yesterday's Wall Street Journal article were "not related to the design
flaw that led to a massive recall of the device a year ago". A Company
spokesperson furthermore stated that the number of problems with balloon non-deflation
were "exceedingly low" and that "You're always going to have
problems with a balloon not deflating or getting stuck." Officials with
the FDA agreed and that the reports are "within expectations" for
the device. The Pioneer Press quotes a stock analyst saying, "It is unclear
why this article was written, given this is an old issue."
(source: Jim McCartney, St. Paul Pioneer Press)
July 13, 2005
Boston
Scientific Stent Problems Persisted
(source: Associated Press)
FDA
sees no more action on stents despite injuries
(source: Reuters)
Stents
Made by Boston Scientific Showed Problems After 2004 Recall
(source: Sylvia Pagan Westphal, Wall Street Journal
-- subscription only)
A front page report in this morning's Wall
Street Journal has raised questions about potential
problems with Boston Scientific's Taxus stent, which
was recalled by the company last summer. The article
details cases (since the recall) in which the balloon
on which the stent is mounted failed to deflate quickly,
causing injury and in one or two cases, death to the
patient. Failure of a balloon to deflate is a complex
issue, that may or may not be a problem with the equipment
itself -- many factors such as the anatomy of the specific
artery, operator technique, etc. can interact. All
devices have complication rates -- the question is
whether the complication rate for a specific device
is out of the ordinary. The FDA has examined these
reports and, as of today, did not see that the adverse
reports warranted any action. As Mark Landy of the
Susquehanna Financial Group pointed out in the Reuters
article above:
" With both drugs and medical
devices, you get bad outcomes from time to time," adding
the Wall Street Journal report followed a series
of recent reports by The New York Times about problems
with medical devices made by Guidant Corp. "It
now appears that medical devices are in cross-hairs
of journalists," he said.
Angioplasty.Org has previously written
about the meaning of product recalls in its article, "What's
A Patient To Do?" -- we will be updating this
as more information is received about the problems
that were raised today.
July 13,
2005
Drug-Eluting
Stents Prove Mettle in Heart Attack Patients
Drug-eluting stents have shown great success in treatment of coronary artery
disease but until now has not been studied in heart attack victims. This study,
published in CCI: Journal of the Society for Cardiovascular Angiography and
Interventions, shows very positive results in this population
(source: Catheterization and Cardiovascular Interventions)
July
1-2, 2005
Boston
Scientific Announces Patent Infringement Verdict Against
Johnson & Johnson
(source: Boston Scientific Corporation)
Cordis
to Ask Judge to Overturn Patent Verdict
(source: Cordis Corporation)
Jury
Finds Infringements on Patents on Stents
(source: Barnaby J. Feder, New York Times -- reg
required)
Boston
Scientific wins suit -- Patent ruling evens score in
legal fight between stent rivals
(source: Ross Kerber, Boston Globe)
Another series of articles and company press releases that discuss the event
surrounding today's jury finding that Johnson & Johnson / Cordis infringed
patents owned by Boston Scientific -- these concern the polymer coating of
drug-eluting stents and the so-called "Ding" patent. Damages will
be decided upon later in August, but this now levels the playing field quite
a bit. The last
trial found that Boston Scientific infringed upon J&J's bare metal
stent design. So in the past month juries have found that the patents for the
stent structure, as well as aspects of the balloon-expandable process, belong
to J&J, but that the patents for the polymer drug-coating process belong
to Boston Scientific. This will, in our view, might to an accomodation down
the line, but first J&J is asking the judge to reverse the jury's decision
and also plans to appeal. Stay tuned.
July 13,
2005
Lack
Of Major Heart Device Trials Hurts Sector's Luster
Article "laments" the lack of major clinical trials, such as the
ones for drug-eluting stents and ICDs -- and paints a picture of the coronary
medical device industry in, as Dr. Eric Topol calls it, the "evergreen
phase" -- matured and not much movement. The article also quotes Paul
LaViolette, COO of Boston Scientific, as saying that catheter-based treatment
of carotid narrowing (stroke prevention) is going to be a growth area. We agree.
(source: Daniel Rosenberg, Dow Jones Newswires)
July 6,
2005
Guidant
Begins Enrollment in European Drug Eluting Stent
Study
The company announced the first patient enrolled in its SPIRIT II drug eluting
stent clinical study for the everolimus coated XIENCE™ V. The cobalt-chromium
stent is in trials in the U.S. and now in Europe.
(source: Guidant Corporation)
July 5,
2005
For
J&J, device rewards outweigh risks--analysts
say
A business overview of where J&J is, considering the recent stent patent
rulings and their impending acquistion of Guidant, a company that has just
gone through a much-publicized recall.
(source: Susan Kelly, Reuters)
June 28,
2005
Boston
Scientific Heads Back to Court
A recounting of the various "trials" and tribulations that Boston
Scientific is going through with lawsuits involving patnet infringement from
Johnson & Johnson / Cordis, settlement of fines with the U.S. Department
of Justice and now, the opening of the trial dealing with a long-standing dispute
with Israeli-based Medinol.
(source: Barnaby J. Feder, New York Times)
June 22,
2005
Guidant
Begins Enrollment in U.S. Drug Eluting Stent Trial
Guidant moves forward with it everolimus drug-eluting stent. Even though Johnson & Johnson
/ Cordis plans on acquiring Guidant later this year, this newest DES trial
has begun -- and it is designed to compare the XIENCE V stent to Boston Scientific's
Taxus.
(source: Guidant Corporation)
June
21, 2005
Patients
Reap Benefits of Heart Health Advance
This press release from Cordis gives an overview of what the introduction of
drug-eluting stents (the Cypher, in particular) has meant for patients. In
our view, the impact of drug-eluting stents has changed the treatment pathways
significantly from what they were only two or three years ago.
(source: Cordis Corporation)
June 21,
2005
Jury
Finds Cordis Patents Infringed by Boston Scientific
Stents
(source: Cordis Corporation)
Boston
Scientific Announces Jury Verdict in Patent Litigation
With Johnson & Johnson
(source: Boston Scientific)
Jury
Rules Against Boston Sci In J&J Stent Patent Trial
(source: Wall Street Journal -- subscribers only)
Boston
Scientific infringed J&J patent-jury
(source: Susan Kelly, Reuters)
Boston
Scientific could face $1B in damages on patent infringements
(source: Boston Business Journal)
A series of articles and press releases regarding today's jury decision that
Boston Scientific's stents infringed on two patents held by Johnson & Johnson
/ Cordis. This not unexpected ruling has no injunctive effect on the current
supply of stents (i.e. Boston Scientific will not have to stop selling its
market-share-leading Taxus stent) although the ruling that the second "Gray
patent" is infringed upon by Boston Scientific's up-and-coming Liberte
stent is potentially troublesome. The actual damages will be decided in another
trial in August. Analysts have said that they could reach $1 billion. (Editor's
Note: In a separate case, soon to go on trial, Boston Scientific is claiming
patent infringement against Cordis for the polymer coating of its drug-eluting
stent.)
June
20, 2005
Next-Generation
TAXUS® Liberte™ Coronary Stent System Registry
Completes First Enrollment Phase
The company announced that it has completed enrollment in the transitional
phase of the world's largest drug-eluting stent registry. The OLYMPIA registry
plans to enroll more than 30,000 patients at more than 600 centers in the United
States, Europe and other international locations.
(source: Boston Scientific Corporation)
June 17, 2005
Medinol
lawsuit heads back to court
Four-years in the making, this dispute has not been resolved through court-suggested
mediation, so on June 27 the parties will find themselves facing each other
in a New York court.
(source: Shirely Yom Tov, Haaretz)
June
9, 2005
Cordis
Corporation to Appeal Court Ruling
(source: Cordis Corporation)
A Dutch court has ruled against Cordis and for Boston Scientific on a patent
issue stemming from the catheter shaft for their balloon catheters, used to
deliver the Cypher drug-eluting stents. The patent issue did not involve the
stent itself. The company plans to appeal the ruling and stated, "Given
current inventory and expanding manufacturing capabilities elsewhere, Cordis
Corporation does not expect a significant impact on its ability to supply the
ex-U.S. marketplace for these products."
May
31, 2005
DES
Prove Popular, But Docs Say Improvements Still Needed
Reporting on a Guidant-sponsored symposium at this year's EuroPCR course in
Paris, Medical Device Daily gives an interesting picture of the current and
near-future state of drug-eluting stents. Dr. Renu Virmani, a frequent critic
of drug-eluting-stent-mania, found Guidant's Xience V everolimus stent superior
in many ways.
(source: Holland Johnson, BioWorld Today Online)
May
25, 2005
Abbott
Launches TriMaxx Coronary Stent and Five New Products for
Vascular Intervention at Paris Course on Revascularization
The company announced that it has launched its next-generation coronary stent,
TriMaxx™, the platform for its much-anticipated investigational drug-eluting
stent, ZoMaxx™, in Europe today. In addition, Abbott also lauvhed five other
vascular products. Chip Hance, president of Abbott Vascular states, "Physicians
in Europe will appreciate TriMaxx' unique stainless steel and tantalum tri-layer
design. Along with the introduction of TriMaxx, the European launch of five
additional products demonstrates our continuing commitment to deliver high-performing
technology that can be relied upon by physicians to build their interventional
practices. All of our products, including our flagship StarClose™ Vascular
Closure System, are developed with the core intention of improving patient
outcomes and enhancing quality of life."
(source: Abbott Laboratories)
May
24, 2005
Conor
Medsystems Announces Positive Twelve-Month Follow-Up
Data From EuroSTAR Pivotal Study
This was a relatively small trial reported at the EuroPCR course, but the results
are interesting. At twelve-month follow-up, the target lesion revascularization
(TLR) rate was 2.9 percent and the rate of cumulative major adverse cardiac
events (MACE) was 7.6 percent. There were no reported cases of stent thrombosis
between the cessation of anti-platelet therapy at six months and twelve-month
follow-up. The principal investigators for this study are Dr. Keith Dawkins
from Southampton, UK and Dr. Antonio Columbo of Milan, well-known to all in
the interventional community.
(source: Conor Medsystems,
Inc.)
May 23,
2005
FDA
Approves 12-Month Shelf Life for Taxus® Stent
System
In a press release, the company announced today that the FDA has extended the
approved shelf-life of its Taxus drug-eluting stent from the current 9 months
to 12 -- it is currently 18 months outside the U.S. The company also notes
that "the new TAXUS U.S. shelf life is longer than any competing product" --
by "any" the company means the only other competing
product, i.e. the Cypher stent, made by Cordis / Johnson & Johnson. It
will be interesting to see if this announcement is followed by a similar extension
for the Cypher -- this occurred last month when the FDA approved both products
for immediate MRI scanning after stenting within a two week period. The current
shelf life for the Cypher stent is 3 months in the U.S. and 5 months outside
the U.S..
(source: Boston Scientific Corporation)
May
17, 2005
Abbott
Enrolls First Patient in Pivotal Zomaxx™ Drug-Eluting
Stent Clinical Trial
The company has enrolled its first patient in the North American phase of its
Zomaxx II trial, approved by the FDA in April. This new stent uses a drug coating
somewhat different than the current "limus" and paclitaxel varieties
-- a coating discovered and produced by Abbott (other stents use drugs licensed
from third parties). Jeffrey W. Moses, M.D., who performed the first interventional
procedure in the ZOMAXX II trial, states in this press release, "I found
the ZoMaxx stent to be highly deliverable. It performed superbly during the
procedure and appears to have enough flexibility to make it a compelling candidate
for use in certain difficult-to-treat cases.... ZoMaxx is also clearly visible
under x-ray fluoroscopy, contributing to its ease of use and the ability to
see its excellent scaffolding during and after stent implantation procedures."
(source: Abbott Laboratories)
May 17, 2005
Gamble
wins big at Boston Scientific
In a "local firm makes good" story, the company moved into the top
spot on the Boston Globe 100 ranking of the best-performing Massachusetts companies
-- it was the first life sciences company to do so. The article provides some
historical perspective on how Boston Scientific initially could not afford
the $40 million asking price to purchase the company that made the first cardiac
stent in 1993 -- Johnson & Johnson bought Cordis and is now Boston Scientific's
chief competitor. But the big story is how Boston Scientific successfully dealt
with a manufacturing defect that caused the recall of virtually all its Taxus
stents last summer (read
our feature on the recall) and increased sales by over $2 billion last
year.
(source: Ross Kerber, Boston Globe)
May
10, 2005
Conor
Medsystems Receives CE Mark Approval for UniStar™ Cobalt
Chromium Stent
The company today announced that its UniStar™ cobalt chromium bare-metal
coronary stent received CE Mark approval in the European Community for the
treatment of de novo coronary artery lesions. Conor also announced today that
the company has received ISO certification of its facility in Athlone, Ireland
for the commercial manufacturing of its proprietary coronary stents including
the UniStar stent and the CoStar™ cobalt chromium paclitaxel-eluting
coronary stent, which it hopes to have approved later this year.
(source: Conor Medsystems, Inc.)
May
5, 2005
Guidant
Receives Approval to Begin U.S. Drug Eluting Stent
Trial
In it press release, Guidant states that the "SPIRIT III is a large-scale
pivotal clinical trial evaluating the safety and efficacy of Guidant's drug
eluting stent system for the treatment of coronary artery disease. This prospective,
randomized, single-blind trial compares XIENCE™ V, an everolimus eluting
coronary stent system utilizing Guidant's cobalt chromium MULTI-LINK VISION® Coronary
Stent System platform, versus the TAXUS® Express 2™ Paclitaxel Eluting
Coronary Stent System. Results of the SPIRIT III trial may be used to obtain
FDA approval for XIENCE(TM) V for the treatment of coronary artery disease.
(source: Guidant Corporation)
May 4,
2005
Cook
to Begin First International Trial of a Paclitaxel-Eluting
Stent for Peripheral Artery Disease
With a U.S. trial already underway, Cook Group will expand its efforts to bring
the world's first paclitaxel-eluting stent for peripheral artery disease (PAD)
to market by launching an international clinical trial, company officials reported
today. The global clinical investigation of Cook's Zilver® PTX™ Drug-Eluting
Stent will enroll 760 patients at up to 50 investigational sites in Europe,
Asia, Australia and Canada.
(source: Cook Incorporated)
May 3-4,
2005
Coated
stents' blood-clot risk may be higher than thought
Another article on the JAMA article (below)
(source: Boston Globe)
Incidence,
Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting
Stents
Abstract of the article published in the May 4 issue of JAMA. The authors'
conclusion is "The cumulative incidence of stent thrombosis 9 months after
successful drug-eluting stent implantation in consecutive "real-world" patients
was substantially higher than the rate reported in clinical trials. Premature
antiplatelet therapy discontinuation, renal failure, bifurcation lesions, diabetes,
and low ejection fraction were identified as predictors of thrombotic events."
(source: Journal of the American Medical Association)
Drug-Coated
Stents Show Shortfalls
An good article with a somewhat misleading headline -- thrombosis, or blood-clotting, always has
been a concern in the use of drug-eluting stents. That is why blood-thinning
drugs, such as Plavix (clopidogrel) or ticlopidine, and aspirin are routinely
prescribed for patients who have had drug-eluting stent placement for at least
3 months, and up to a year in some practices. So a study published in JAMA
(link to the abstract is listed above) of 2,229 patients conducted in 3 German
and Italian hospitals is generating headlines because the "real world" thrombosis
rate is double what has been observed in clinical trials for these devices
-- "double" means 1.3% in this study, as contrasted with 0.4-0.6%
in clinical trials where one would assume post-procedural compliance was higher.
For a perspective on this news, read "Voice
in the Ear" -- our Editor's blog.
(source: Ed Edelson, HealthDay)
Drug-eluting
stents: some bare facts
A "must read": in an October 2004 letter, commenting on a study of
late-stent-thrombosis, Dr. Eisenberg, of Montreal, Quebec, Canada discusses
the whole topic of stent thrombosis in the era of drug-eluting stents -- an
excellent overview which puts today's headlines into perspective -- one of
the major problems, as reported in the JAMA study from Milan, is the premature
discontinuation of antiplatelet therapy in drug-eluting stent patients. For
those whose do not have a subscription to The Lancet, this
article from Journal Club has a good summary.
(source: Mark J Eisenberg MD, The Lancet -- requires subscription
to read)
April
20, 2005
Boston
Scientific Announces Publication of Six TAXUS IV Articles
in Prestigious Journal of American College of Cardiology
A half-dozen studies from TAXUS IV data are reported in today's JACC, ranging
in subject matter from gender difference to treatment of diabetics.
(source: Boston Scientific Corporation)
April 20,
2005
CYPHER® Sirolimus-Eluting
Coronary Stent Receives FDA Approval for MRI Scans
Immediately Following Implantation
Following their approval two weeks ago for the Taxus stent, the FDA is now
satisfied that Johnson & Johnson's Cypher is also safe for immediate MRI
imaging. Patients no longer have to wait two months before undergoing an MRI
test. This announcement means that both drug-eluting stents available in the
U.S. are safe for immedtae MRI.
(source: Cordis Corporation)
April
14, 2005
Boston
Scientific Announces FDA Approval and Launch of Liberte™ Coronary
Stent System
In a significant step towards approval of what will almost certainly be the
first second-generation drug-eluting stent in the U.S. next year, the company
announced today that the F.D.A. has approved the Liberte stent -- the bare
metal version -- which serves as the platform for the TAXUS Liberte stent, already
available in 18 international markets. Boston scientific plans to launch
the new drug-eluting stent in Europe later this year, and hopes for a mid-2006
approval in the U.S. The FDA approval for the Liberte stent can be found here.
(source: Boston Scientific Corporation)
April 12, 2005
Boston
Scientific Announces Start of Enrollment in Groundbreaking
Clinical Trial Comparing Drug-Eluting Stents to Cardiac
Surgery
The company announced that a major clinical trial comparing the Taxus paclitaxel-eluting
stent with bypass surgery (CABG) has begun with the first patient enrolled
at Institut Hospitalier Jacques Cartier in Massy, France by Dr. Marie-Claude
Morice (who was principal investigator for Johnson & Johnson's REALITY
trial). The SYNTAX Trial will enroll over 4,200 patients at up to 90 sites
in Europe and the United States and will study patients with triple-vessel
and left main disease, the most complex patient set studied in such a trial.
As Dr. Morice stated, ""The drug-eluting stent revolution has led
us to the point where a randomized comparison of the TAXUS system with surgery
in the highest-risk patients is critical....The results of this study may profoundly
change the practice of medicine." Principal investigators for the study
are Professor Friedrich Mohr, M.D., Program Director of the Heart Center/Cardiothoracic
Surgery, University of Leipzig, Germany and Professor Patrick Serruys, M.D.,
Ph.D., Chief of Interventional Cardiology, Thoraxcenter-Erasmus University
Rotterdam, The Netherlands.
(source: Boston Scientific Corporation)
April 12,
2005
Medtronic
Announces First Patient Enrollment in the ENDEAVOR
IV Clinical Trial
Medtronic announces the final phase of its ENDEAVOR Clinical Program aimed
at gathering clinical data to secure approval for its drug-eluting stent. The
co-principal investigators of the ENDEAVOR IV trial are Martin B. Leon, M.D.
Columbia University Hospital, New York, and David M. Kandzari, M.D., Duke University
Medical Center, Durham, N.C. Endeavor IV compares the Medtronic stent to the
Taxus; Endeavor III is a comparison with the Cypher and its results are expected
to be presented at this year's TCT.
(source: Medtronic, Inc.)
April 10,
2005
Guidant
jobs may be at risk in merger deal
There's talk that the impending merger with Johnson & Johnson may cause
Guidant facilities in California to cut staff.
(source: Laura Cutland, Silicon Valley/San Jose Business Journal,
courtesy MSNBC)
April 7, 2005
Abbott
Receives FDA Approval to Begin ZOMAXX II U.S. Drug-Eluting
Coronary Stent Trial
Looking to an anticipated U.S. approval for their drug-eluting stent in the
second half of 2007, Abbott is beginning enrollment of 1,670 coronary artery
disease patients in up to 80 centers. The press release states: "The trial
will compare clinical outcomes in patients who are treated with Abbott's investigational
ZoMaxx drug–eluting coronary stent with patients who receive Boston Scientific's
Taxus™ Express2™ drug–eluting stent. The primary endpoint
of ZOMAXX II is 9–month ischemia–driven target vessel revascularization,
a clinical measure of the need to conduct another intervention (stent, brachytherapy
or surgery) to reopen a vessel previously treated with a stent."
(source: Abbott Laboratories)
April 6,
2005
Boston
Scientific First to Market with Full Range of Large
Vessel Drug-Eluting Stent System Sizes
The company announced today that it has received CE Mark for three large vessel
sizes (4.0mm, 4.5mm and 5.0mm) of its TAXUS stent in Europe and other international
markets.
(source: Boston Scientific Corporation)
April 5,
2005
Boston
Scientific's TAXUS® Express2™ Paclitaxel-Eluting
Stent System First Drug-Eluting Stent to Receive
FDA Approval Allowing Immediate MRI Exams
In good news for patients, the FDA has approved Boston Scientific's Taxus drug-eluting
stent, as well as its bare metal uncoated version, the Express2, allowing MRI
scans immediately after implantation. MRI is utilized in many patients who
also have had stents placed, but previously they had been advised to wait up
to two months between the stenting and MRI.
(source: Boston Scientific Corporation)
March
23, 2005
First
U.S. Drug-Eluting Stent Trial To Treat Peripheral
Arterial Disease Enrolls First Patient At Stanford
University Medical Center
(source: Cook Incorporated)
A trial to test if a paclitaxel-coated drug-eluting stent can help solve the
problem of peripheral (leg) artery disease (PAD) has begun with the first patient
enrolled at Stanford. The Zilver PTX trial is being conducted initially in
10 U.S. medical facilities and will enroll 60 patients, with an expanded trial
likely pending further FDA review.
March
23, 2005
Conor
Medsystems Receives Conditional IDE Approval From the FDA
to Begin COSTAR II Pivotal Clinical Trial
The company has gained FDA approval to begin a clinical trial of their unique
stent for the treatment of restenosis. The CoStar™ stent is made of cobalt
chromium, not stainless steel, and contains small reservoirs which contain
the drug paclitaxel, the same drug that is used in the polymer coating of Boston
Scientific's Taxus stent, against which it will be compared. The results of
this clinical trial will be interesting in that the same drug is being used
-- just being delivered in a different way.
(source: Conor Medsystems, Inc.)
March
15, 2005
Conor
Medsystems Signs Multi-Drug Agreement to Develop Next-Generation
Reservoir-Based Drug-Eluting Stents
Conor MedSystems, a developer of a unique drug-reservoir-based stent has entered
into an agreement with Novartis Pharma AG to look at three different drugs
to evaluate their efficacy in preventing restenosis.
(source: Conor Medsystems, Inc.)
(Special Section)
TAXUS vs. CYPHER: The Latest Episode of "Stent Wars" Debuts at
the American College of Cardiology Annual Meeting
"All of these trials are
underpowered and unfortunately we are going to get
a lot of confusion when we look at these small underpowered
studies showing big differences." |
-- Gregg W. Stone,
MD, Principal Investigator for TAXUS V (March 6, 2005)
|
"We are...not selecting our
attitude for the patient on only one trial. All that
has to be put in perspective... because there is no
one good and one bad, one ugly and one marvelous. The
reality's not there. We are in small differences and
I think we need much more data to dramatically change
the practice." |
-- Marie-Claude
Morice, MD, Principal Investigator for REALITY (March
6, 2005) |
March 9, 2005
REALITY,
ISAR-DIABETES and SIRTAX: Trials and Tribulations
Commentary from the Editor of Angioplasty.Org's Blog about the results
of Sunday's drug-eluting stent presentations at the ACC.
(source: Burt Cohen, The Voice in the Ear)
March 7, 2005
Boston
Sci Defends Stent's Safety, Will Monitor Issue
Boston Scientific executives respond to results from the REALITY trial
that indicated a higher-than-normal incidence of thrombosis (blood-clotting)
with the Taxus stent. They are monitoring these safety issues, but said
that there isn't a major problem and that a competitor is blowing things
out of proportion. The higher thrombosis rates seen in the REALITY trial
have not been present in the many thousands of patients studied in other
trials of the Taxus stent.
(source: Daniel Rosenberg, Dow Jones Newswires, CNN
Money -- no longer online)
March 7, 2005
Boston
Scientific's Taxus stent endures challenge by rival J&J
A different newspaper has a slightly different view of the ACC stent
studies.
(source: Ross Kerber, Boston Globe)
March 7, 2005
J&J's
Eleventh-Hour Victory
Adding to the interpretations, Forbes cites a study (SIRTAX) presented
later in the day on Sunday which showed an advantage for the Cypher stent
over the Taxus in several parameters. Presented earlier, the largest
study, REALITY, showed no advantage, but did show a higher thrombosis
(blood-clotting) rate for the Taxus stent. The SIRTAX study, on the other
hand, showed a higher thrombosis rate for the Cypher.
(source: Matthew Herper, Forbes.com)
March 6, 2005
USA
Today: Studies of rival stents suggest one is better
Milwaukee
Journal Sentinel: In tests, one stent works the
best
The headlines regarding the various studies presented at the ACC are
interesting, in light of the declaration of Dr. Marie-Claude Morice,
primary investigator for REALITY, the largest of the studies: "...there
are not enough data to select one DES over the other." FYI, the
study, unnamed in the Sentinel article, is the SIRTAX.
(sources: Steve Sternberg, USA Today / John Fauber,
Milwaukee Journal Sentinel)
March 6, 2005
Drug-Coated
Stents Transform Heart Care
An overview from Associated Press of all the studies presented today
at the ACC add up to a clear picture that drug-coated (a.k.a. drug-eluting)
stents represent a major advance in the treatment of coronary artery
disease.
(source: Marilyn Marchione, AP Medical Writer)
March 6, 2005
Arts
II Clinical Study Shows Promising Results for the CYPHER® Sirolimus-Eluting
Coronary Stent In Patients With Multi-Vessel Disease
The question posed: can drug-eluting stents match bypass surgery in the
treatment of multivessel disease? In the words of principal investigator
Professor Patrick Serruys, The Thoraxcenter, Erasmus Medical Center,
Rotterdam, Netherlands, "For years, physicians have debated the
merits of stent procedures versus coronary artery bypass grafting in
challenging patients with lesions in two or more vessels...these data
suggest that percutaneous procedures using the CYPHER® Stent may
be as effective as surgery in these patients and much less invasive."
(source: Johnson & Johnson / Cordis)
March 6, 2005
REALITY
Trial: Clinical Events at 8 Months
A chart summarizing the clinical events at the end of the 8-month study
period for both the Cypher and Taxus stents.
(source: Angioplasty.Org)
March 6, 2005
Results
of REALITY Trial Reaffirm Safety and Efficacy of TAXUS® Express2™ Paclitaxel-Eluting
Stent System
Boston Scientific's press release on the result of the Johnson & Johnson-sponsored
REALITY trial.
(source: Boston Scientific Corporation)
March 6, 2005
Johnson & Johnson
Stent Study Falls Short
Although differences in the two stents (CYPHER vs. TAXUS) were noted
in J&J's press release below, most readings of the REALITY trial
are that it failed to prove that one drug-eluting stent was superior.
(source: Reuters)
March 6, 2005
Stent
Test Suggests Not Much Difference Between Rivals
The lead sentence says it all: "The coronary stent showdown looks
like a draw, although one with a good outcome." The good outcome
is the point. Patients have been and will continue to benefit significantly
from drug-eluting stent technology
(source: TheStreet.com)
March 6, 2005
REALITY
Trial Data Suggest Drug-Eluting Stents Differ Significantly
in Rate of Blood Clot Formation-Stent Thrombosis
The company's press release on the much-anticipated REALITY trial, which
compared the CYPER to the competing TAXUS drug-eluting stent, discusses
a specific finding of the investigators, along with a few others. More
commentary will be coming out over the next couple of days.
(source: Johnson & Johnson / Cordis)
March 6, 2005
TAXUS
V Demonstrates Excellent Safety and Efficacy Results in
Most Challenging Lesions and High-Risk Patients
The company reports that results of a difficult-to-treat patient population
have met the primary goals of the study. These cases included small vessels,
large vessels and long lesions requiring multiple overlapping stents,
according to Boston Scientific, "...the most challenging lesions
and highest-risk patients ever studied in a randomized, controlled drug-eluting
stent trial in the United States."
(source: Boston Scientific Corporation)
|
March 6,
2005
Clinical
Results Of Pivotal Trial Show Endeavor™ Drug
Eluting Stent Provides Significant Treatment Effect
In Patients With Coronary Artery Disease
The final ENDEAVOR II clinical data was very good and will move Medtronic's
entry into the drug-eluting stent arena forward. Dr. William Wijns of Belgium
and Co-Principal Investigator of the trial stated, "Overall the clinical
results are impressive and show that more than 95 percent of the patients who
received an Endeavor stent in the trial required no further treatment or revascularization
at the original treatment site at the nine month assessment period."
(source: Medtronic, Inc.)
March 5, 2005
Conor
Medsystems Announces Positive Angiographic and Clinical
Results for EuroSTAR Drug-Eluting Stent Trial
The company today reported six-month follow-up angiographic and clinical data
from their EuroSTAR study evaluating its CoStar™ cobalt chromium paclitaxel-eluting
stent in a complex patient cohort. The in-stent binary restenosis rate was
3.4 percent and the in-stent late loss was 0.26 millimeters. The in-segment
binary restenosis rate was 4.7 percent and the in-segment late loss was 0.07
millimeters. As previously reported, the target lesion revascularization (TLR)
rate was 1.7 percent and the rate of cumulative major adverse cardiac events
(MACE) was 4.8 percent.
(source: Conor Medsystems, Inc.)
March 4, 2005
Boston
Scientific Announces Completion of Acquisition of
Advanced Stent Technologies, Inc.
AST has designed stent systems that treat bifurcations, the place where a single
blood vessel branches into two. These have historically been difficult to treat
and have had greater chance of recurrence. The company hopes that this new
technology combined with the Taxus paclitaxel polymer might change those outcomes.
(source: Boston Scientific Corporation)
March 3,
2005
Heart
Meeting To Focus On J&J Stent Vs Boston Scientific
An overview from DowJones on the various trials and presentations coming up
this weekend at the annual ACC meeting, which the author states "should
be the most important meeting on drug-eluting stents since 2003."
(source: Daniel Rosenberg, Dow Jones Newswire)
March 3, 2005
Medtronic
Announces Key Activities At American College Of Cardiology
Scientific Session
The company announces the various clinical trial presentations and corollary
activities around the upcoming ACC. Key sessions include data on Medtronic's
Endeavor II trial for their drug-eluting stent.
(source: Medtronic, Inc.)
March 3, 2005
Boston
Scientific to Announce Results from its TAXUS V Drug-Eluting
Stent Clinical Trial, Studying Most Challenging Lesions
and Highest-Risk Patients
Company press release lists the scheduled presentations and symposia they are
sponsoring around the upcoming American College of Cardiology meeting in Orlando,
Florida. The TAXUS V studies will show 9-month data from the latest TAXUS trial
which, according to the company, looked at "higher-risk patient population,
including patients with small vessels, large vessels and long lesions requiring
multiple overlapping stents -- the most challenging lesions and highest-risk
patients ever studied in a randomized controlled drug-eluting stent trial in
the U.S."
(source: Boston Scientific Corporation)
March 2,
2005
Boston
Scientific fires at J&J study
Paul LaViolette, COO of Boston Scientific, commenting on the upcoming REALITY
trial results (to be presented on Sunday morning) of J&J's CYPHER stent
vs. Boston Scientific's TAXUS, says, ''It was designed to show Cypher's superiority
over Taxus, and it will therefore fail...."
(source: Ross Kerber, Boston Globe)
February
24, 2005
CYPHER® Sirolimus-Eluting
Coronary Stent to Be Featured in Late-Breaking Clinical
Trial Presentations at 2005 American College of Cardiology
Scientific Session
A company press releases states that: "Four late-breaking presentations
on Sunday, March 6 will examine the CYPHER® Stent's clinical performance
across a variety of patient populations. Among the presentations at the international
medical conference will be results from the REALITY Trial, a randomized prospective
global study that examines the CYPHER® Stent versus the Taxus Stent; the
ARTS-II trial, which details long-term results of a multi-center prospective,
non-randomized study of multi-vessel stenting; the SIRTAX trial, an independent
randomized comparison of the CYPHER® Stent with Taxus Stent for coronary
revascularization; and the ISAR-DIABETES trial, an independent German study
designed to test the safety and efficacy of the CYPHER® Stent and the Taxus
Stent in the treatment of patients with diabetes."
(source: Cordis Corporation)
February 24,
2005
Reuters
Summit-All Eyes On Medtronic in Stent Wars
Results from Medtronic's drug-eluting stent trial, Endeavor II, will be presented
along with those of a number of trials at the upcoming American College of
Cardiology Annual Meeting (ACC
'05).
(source: Debra Sherman, Reuters)
February 23,
2005
Boston
Scientific Announces Start of Enrollment in World's
Largest Drug-Eluting Stent Registry
In a press release, the company states that the "TAXUS OLYMPIC registry
plans to enroll more than 30,000 patients at more than 600 centers in the United
States, Europe and other international locations. The registry is designed
to collect and analyze 'real-world' clinical outcomes data for the TAXUS® Liberte™ paclitaxel-eluting
stent system in the treatment of patients with coronary artery disease."
(source: Boston Scientific Corporation)
February
23, 2005
Reuters
Summit-Boston Scientific sees good stent trial
Speaking to the Reuters Medical Devices Summit, Paul LaViolette, Chief Operating
Officer of Boston Scientific, expressed confidence that two important clinical
trials, whose results are to be announced at the upcoming ACC
'05, will show favorable results for the company: REALITY, which compares
J&J's CYPHER stent to Boston Scientific's TAXUS (the trial is sponsored
by J&J) and TAXUS V, which studies very sick patients who have been treated
with the TAXUS stent.
(source: Julie Steenhuysen, Reuters)
February
23, 2005
Reuters
Summit-Abbott Sees Stent in '06 Outside U.S.
Richard Gonzalez, Chief Operating Officer of Abbott's medical products group,
told the Reuters Medical Devices Summit that the company is confident that
their drug-coated stent should become available outside the U.S. next year
and reach the U.S. market by 2007.
(source: Julie Steenhuysen, Reuters)
February 22,
2005
Boston
Scientific Announces Completion of Enrollment in
Pivotal Clinical Trial For Next-Generation Paclitaxel-Eluting
Coronary Stent System
The company announced that it has completed enrollment of 872 patients in the
ATLAS trial, designed to evaluate the safety and efficacy of a slow-dose formulation
of the new Taxus® Liberte™ thin-strutted stent. Boston Scientific
is planning to launch this second-generation drug-eluting stent in Europe later
this year.
(source: Boston Scientific Corporation)
February 21, 2005
Coated
Stents Superior Over the Long Term: Study finds advantages
over bare-metal stents after three years
A report on study appearing in Circulation from Clinique Pasteur in
Toulouse, France, looking at data from the RAVEL clinical trial
(source: Ed Edelson, HealthDay)
February
18, 2005
Conor
Countersues Angiotech Over Patent
Keeping in the news (see yesterday's press release below) Conor has filed a
lawsuit in Britain against Angiotech Pharmaceuticals Inc.'s patented paclitaxel
technology). This comes two weeks after Angiotech and Boston Scientific Corp.
sued Conor in the Netherlands for alleged patent infringement. In their press
release, Angiotech states that they, "...will pursue and defend against,
to the fullest, any and all actions of Conor Medsystems respecting Angiotech's
extensive patent portfolio and pioneering technology."
(source: Associated Press)
February 17, 2005
Conor
Medsystems Announces Positive Six-Month Follow-Up
Data from EuroSTAR Pivotal Study
In its press release, Conor Medsystems says that a study presented at the annual
Joint Interventional Meeting in Rome, Italy supports the safety and efficacy
of the company's CoStar(TM) Cobalt Chromium Paclitaxel-Eluting Coronary Stent
(source: Conor Medsystems, Inc.)
February
14, 2005
Stories
of Survival and Hope Mark the One Million Patient Milestone
For the CYPHER® Sirolimus-eluting Coronary Stent
Cordis announced today that the company had passed a milestone: more than one
million patients have now received the CYPHER® Sirolimus-eluting Coronary
Stent worldwide; that comes out to around 1.5 million CYPHER stents. The press
release profiles two patients who have resumed normal active lifestyles and
also quotes Martin Leon, M.D. of Columbia Presbyterian Hospital in New York
City, the first U.S. cardiologist to use the CYPHER: "This medical technology
of drug-eluting stents has introduced a new era in cardiology where patients
can be treated less invasively and have a better chance of avoiding a repeat
cardiac procedure."
(source: Cordis Corporation)
February
3, 2005
Caution
Against Using Certain Drugs to Unclog Heart Arteries
This report on a study by Dartmouth Medical School cardiology researchers discusses
the discoveries of a dual mechanism of why arteries reclose after stenting,
and what implications their research might have in the development of drug-eluting
stents.
(source: Medical News Today)
February 2, 2005
Boston
Scientific maps out post-Taxus strategy
Boston Scientific seeks new markets
Two business views (one from Minneapolis, the second from Boston) discussing
presentations made in yesterday's analysts meeting and what's in the medical
device pipeline at Boston Scientific
(source: Janet Moore, Star Tribune (free registration required to
read) / Ross Kerber, Boston Globe )
February
1, 2005
Stent
Sales Boost Boston Scientific
The company reports that its fourth-quarter profit more than doubled to $297
million, as a result of its TAXUS drug-eluting stent sales.
(source: Mark Jewell, Associated Press)
February 1, 2005
Stent
Maker's Hearty Returns
A positive take from The Fool on today's quarterly report by Boston Scientific
and a look to the future competition.
(source: Stephen D. Simpson, Motley Fool)
January 31, 2005
Price
fight is looming over stents: Johnson & Johnson
takes on rival Boston Scientific
J&J seems to have cut its price on drug-eluting stents. This article quotes
Dr. Joe Kozina, a cardiologist at Mercy General Hospital in Sacramento, "...he's
been offered the lower prices by Johnson & Johnson salespeople. But he
hasn't stopped using mostly Taxus stents, saying they are easier to place in
blood vessels. 'Pricing makes no difference if I can't get the stent into the
patient...'"
(source: Ross Kerber, Boston Globe)
January
31, 2005
Physician
Feedback Is Extremely Positive as Boston Scientific Completes
Initial Launch of TAXUS® Liberte™ Paclitaxel-Eluting
Stent System
Maurice Buchbinder, M.D., of the Foundation for Cardiovascular Medicine in
San Diego used the new 2nd-generation drug-eluting stent during a recent live
demonstration course in Singapore and he comments, "Despite somewhat challenging
anatomy, the TAXUS Liberte stent system performed very nicely, crossing the
lesions with ease and conforming to the anatomy very well. The angiographic
results were superb."
(source: Boston Scientific Corporation)
January
27, 2005
Is
overdilatation of 3.0 mm sirolimus-eluting stent associated
with a higher restenosis rate?
Answer: No. A study from Antonio Colombo's group in Milan addressed the questions
raised in the fall of 2003 as to whether there might be a negative effect to
over-expanding a 3.0mm Cypher stent to 3.5 or 4.0mm using a balloon and found
no increase of restenosis. The abstract ends, "These data should lessen
concern that overdilation may dilute the beneficial effects of Sirolimus-Eluting
Stents."
(source: Catheterization and Cardiovascular Interventions -- abstract)
January 27, 2005
ARIAD
Announces Collaboration with Medinol, Stent Technology
Leader, to Develop AP23573 Drug-Delivery Stents
A triumverate of medical device manufacturers & a pharma firm specializing
in new oncology drugs are teaming up to develop a new drug-eluting stent: ARIAD
will supply its mTOR inhibitor, AP23573 to put on a stent developed by the
privately-held Israeli firm Medinol, maker of the NIR® stents, with a polymer
to be co-developed with W. L. Gore & Associates, a company with a long
history in the vascular graft field.
(source: ARIAD Pharmaceuticals, Inc.)
January 19,
2005
Boston
Scientific Announces Implantation of Millionth TAXUS® Express2™ Coronary
Stent System
It's been an interesting week for Boston Scientific -- Monday saw the launch
of its second-generation Liberte drug-eluting stent in 18 countries; today
the company announced the 1,000,000th Taxus drug-eluting stent implanted. Gregg
Stone, M.D. of Columbia University Medical Center, New York, a strong proponent
of drug-eluting stents (see
our interview) states, "This is a noteworthy milestone for
Boston Scientific, for physicians and for patients. This product has truly
revolutionized how we treat coronary artery disease and dramatically advanced
the practice of interventional cardiology."
(source: Boston Scientific Corporation)
January 18, 2005
A
prospective randomized comparison between paclitaxel
and sirolimus stents in the real world of interventional
cardiology: The TAXi Trial
A small study from the Clinique Cecil, Lausanne, Switzerland of 202 patients
found no "real world" difference between sirolimus-based and paclitaxel-based
drug-eluting stents (i.e. Cypher vs. Taxus). Outcomes and adverse events were
similar -- both very good statistically.
(source: Journal of the American College of Cardiology -- free ACC
registration required to read abstract)
January
17, 2005
Boston
Scientific Is First to Market With Next-Generation Drug-Eluting
Stent System
The new second generation Liberte drug-eluting stent is being launched today
in 18 countries: Bahrain, Chile, Costa Rica, Dominican Republic, India, Indonesia,
Kuwait, Lebanon, Malaysia, Panama, Peru, Philippines, Saudi Arabia, Singapore,
South Africa, Thailand, Turkey and Venezuela. The company describes the system,
as follows: "The Liberte stent features the Veriflex™ stent design,
a highly flexible cell geometry with thin struts and uniform cell distribution.
This new platform offers improved deliverability and conformability in challenging
anatomy. It also features the enhanced TrakTip™ catheter tip, mounted
on the Maverick2™ delivery catheter, which provides better lesion crossability.
In addition, TrakTip has a low lesion-entry profile, which further improves
crossability."
(source: Boston Scientific Corporation)
January 16, 2005
Cordis
sets sights on stent lead
Story about the current state of drug-eluting stents from the state of Florida,
home of Cordis.
(source: Glenn Singer, Sun-Sentinel)
January
14, 2005
Johnson & Johnson
Withdraws 300 Stents from Market
A manufacturing defect in a small number of drug-eluting Cypher stents has
caused Johnson & Johnson to withdraw them from the market. A second article
in the New York Times, "J.&J.
Recalls 300 Heart Stents After Defects Are Found in 6" adds
that these stents were made in the company's Puerto Rico facility which "was
cited last year by the Food and Drug Administration for violations of manufacturing
standards."
(source: Reuters / Barnaby J. Feder, New York Times)
(Special Section)
JAMA Study: Drug-Eluting Stents Superior to Balloon Angioplasty for In-Stent
Restenosis
January 12, 2005
Small
Clinical Trial Gives Johnson & Johnson
Stent a Bit of a Lift
Johnson & Johnson / Cordis is hoping that publication of this German
trial (below) will give credence to their contention that the Cypher
drug-eluting stent may be superior to rival Boston Scientific's Taxus.
It's important to note that the Cypher vs. Taxus comparison was only
a secondary part of this trial, which was designed primarily to compare
drug-eluting stents with POBA (Plain Old Balloon Angioplasty) for treating
bare-metal stents that had closed up -- also that this portion involved
only 100 patients, which some cardiologists (and Boston Scientific) feel
is too small to make valid statistical comparisons. Nevertheless, of
the 100 patients, the rate for needing a third procedure to open up reclogged
arteries was 18 in the Taxus group and only 9 in the Cypher group. For
a broader comparison, the cardiology community (not to mention the investment
community) is looking towards the REALITY Trial results to be announced
in March at the Annual ACC Meeting. The two stents are different in their
design, but mostly are different in the drug used to suppress restenosis.
(source: Barnaby J. Feder, New York Times -- free NYT
registration required)
January 11, 2005
Sirolimus-Eluting
Stent or Paclitaxel-Eluting Stent vs Balloon
Angioplasty for Prevention of Recurrences
in Patients With Coronary In-Stent Restenosis
The conclusion of the study reads, "...the results of this randomized
controlled trial demonstrate that a strategy based on sirolimus- or paclitaxel-eluting
stents is superior to conventional balloon angioplasty for the prevention
of recurrent restenosis in patients with in-stent restenosis. They also
suggest that in this high-risk subset of patients, sirolimus-eluting
stents may be superior to paclitaxel-eluting stents."
(source: Journal of the American Medical Association
- JAMA)
January 11, 2005
J&J
Stent May Be Winner
A Wall Street view of the recent study published in JAMA (above).
(source: Robert Steyer, TheStreet.com)
January 11, 2005
Drug-Coated
Stents Best If Artery Closes Again
An excellent report on the JAMA report, this piece quotes Steve Nissen,
MD of the Cleveland Clinic, pointing out how this study is a beat behind
medical practice -- the patients in this study all originally had bare-metal
stents which restenosed -- today, drug-eluting stents are used almost
exclusively. It remains to be seen if the results would hold true in
current practice. Also, regarding the CYPHER vs. TAXUS results, he states
that if a patient returns with restenosis in a CYPHER stent, he uses
a TAXUS to treat the in-stent restenosis, and vice-versa.
(source: Ed Edelson, HealthDay)
|
January 6,
2005
Corautus
Genetics Announces Publication of Gene Therapy Approach
to Vascular Disease Using Stents in Circulation
In publication of preclinical results, the company states that delivery of
VEGF-2 to blood vessels using drug-eluting stents was feasible and that this
delivery led to accelerated growth of healthy endothelial cells while reducing
pathological thickening of the artery ("neointima formation," or
scarring) associated with restenosis. This could be very important since current
drug-eluting stent medications work by suppressing endothelial growth in order
to prevent restenosis. The studies build on a foundation of work started by
the late Dr. Jeffrey Isner of St. Elizabeth's Medical Center in Boston (see
our video clip).
(source: Corautus Genetics)
January 5,
2005
Medtronic
loses patent case over heart stents
A federal judge ruled that two of Medtronic's stent devices used to treat clogged
heart arteries infringed a patent held by rival Guidant, and that stents offered
by Guidant and Boston Scientific did not infringe Medtronic's Boneau**
patents (these patents were acquired when Medtronic purchased AVE about 10
years ago). **(Editor's note: everywhere in the media, reference is made to
the "Boneau" patents, but the inventor is Michael
D. Bonneau -- 2 N's in the name. Oddly enough, all
but 2 of the patents filed with the U.S. Patent Office list a "Michael
D. Boneau" as inventor. Did an "N" get dropped somewhere along
the line?)
(source: Reuters)
January 2,
2005
Threat
to health chiefs who ration cardiac treatment
Scotland's Minister for Health and Community Care Andy Kerr has warned a number
of local health boards to approve use of drug-eluting stents -- some are not
reimbursing for the expensive devices which have been shown to reduce restenosis.
About 60% of English patients get the stents, while in Scotland only 5%, despite
Greater Glasgow having Europe's second worst rate of heart disease.
(source: Liam McDougall, Sunday Herald) |
Click
here for more information about the following ads
|
|